Prime Medicine, Inc.
Price Action
Technical Summary
WEAKENINGPrime Medicine, Inc. is in a technical downtrend, trading below key resistance levels with a broken trend structure. Relative strength is weak (RS Rating: 41), showing significant lag compared to the market leaders. Earnings growth of 29% provides fundamental context to the price action. However, price is extended 22% above the 50-day line, increasing the risk of a mean reversion.
Trend Template (Minervini)
Price vs Moving Averages
| Period | Value | Spread | Signal |
|---|---|---|---|
| 20 SMA | $3.29 | +21.28% | ABOVE |
| 50 SMA | $3.27 | +21.97% | ABOVE |
| 100 SMA | $3.48 | +14.65% | ABOVE |
| 150 SMA | $3.60 | +10.76% | ABOVE |
| 200 SMA | $3.93 | +1.57% | ABOVE |
Price Performance
Technical Indicators
Risk Profile
Volume Analysis
Earnings Momentum
Growth Trends
Compounded Sales Growth
Compounded Profit Growth
Stock Price CAGR
Return on Equity
Key Metrics
Frequently Asked Questions
Is PRME in an uptrend right now?
PRME has a trend score of 1/4 based on Minervini's Stage Analysis. Currently showing broken structure - 1 of 4 trend criteria are met.
Is PRME overbought or oversold?
PRME's RSI (14) is 68. The stock is in neutral territory, neither overbought nor oversold.
Is PRME outperforming the market?
PRME has a Relative Strength (RS) Rating of 41 out of 99. PRME is currently lagging the broader market.
Where is PRME in its 52-week range?
PRME is trading at $3.99, which is 57% of its 52-week high ($6.94) and 31% above its 52-week low ($2.67).
How volatile is PRME?
PRME has a Beta of 2.31 and 52-week volatility of 94%. It's more volatile than the S&P 500 - expect bigger swings.